SynBiotic

Overview
Price performance
Financials
Research
Thematics

SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.

Latest Insights

Consumer |
Outlook

16.09.24

SynBiotic — Platform primed for growth

Consumer |
Outlook

09.05.23

SynBiotic — Building the platform

Consumer |
Update

09.08.22

SynBiotic — Management update – on track

Consumer |
Update

06.12.21

SynBiotic — Further acquisitions

Visit Website

Sector

Consumer

Equity Analyst

Russell Pointon

Director of Content, Consumer and Media

Key Management

Daniel Kruse

CEO

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(3.8)	(24.8)	12
Relative	(5.8)	(27.4)	(4.9)
52 week high/low	€13.9/€2.9

Financials

SynBiotic has built up a leading platform company that spans the hemp and cannabis industry to cover the full value chain, from cultivation through to sales. Management buys and builds ventures that create and market hemp, cannabis and cannabinoid products for both medical and recreational use, while continually seeking investments in exciting new verticals. Recreational cannabis use has recently been partially legalised in Germany, while the same legislative changes have benefited the medicinal market. Having built its platform prior to these changes, SynBiotic is seeing its investments bear fruit and we believe it is well-positioned for any further relaxation in cannabis legalisation in Germany.

Research

Outlook

Consumer

09.05.23